产品说明书

Rufinamide

Print
Chemical Structure| 106308-44-5 同义名 : CGP 33101;E 2080;Inovelon.;Brand name: BANZEL;RUF 331
CAS号 : 106308-44-5
货号 : A193932
分子式 : C10H8F2N4O
纯度 : 99%
分子量 : 238.194
MDL号 : MFCD00865314
存储条件：

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 50 mg/mL(209.91 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：

IP 4% DMSO+2% Tween80+40% PEG300+water 1 mg/mL clear

PO 0.5% CMC-Na 62 mg/mL suspension

生物活性
靶点

  • Sodium Channel
描述 Rufinamide is an antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02205931 Epilepsy Phase 4 Recruiting June 2019 United Kingdom ... 展开 >> Birmingham Children's Hospital Recruiting Birmingham, United Kingdom, B4 6NH Contact: Shakti Agrawal, MBBS    0044 1213338149    shakti.agrawal@bch.nhs.uk    Principal Investigator: Shakti Agrawal, MBBS          Bristol Royal Hospital for Children Recruiting Bristol, United Kingdom, BS2 8AE Contact: Andrew Mallick, FRCPCH          Principal Investigator: Andrew Mallick          Addenbrooke's Hospital Recruiting Cambridge, United Kingdom, CB2 0QQ Contact: Alasdair Parker, MA    0044 1223 245151    alasdair.parker@addenbrookes.nhs.uk    Principal Investigator: Alasdair Parker, MA          Lancashire Teaching Hospitals NHS Foundation Trust Recruiting Lancashire, United Kingdom Contact: Helen Basu       Helen.Basu@lthtr.nhs.uk    Principal Investigator: Helen Basu          Leeds Teaching Hospital Recruiting Leeds, United Kingdom, LS1 3EX Contact: Helen McCullagh, RCPCH    0044 113 243 2799    h.mccullagh@nhs.net    Principal Investigator: Helen McCullagh, RCPCH          Alder Hey Children's Hospital Recruiting Liverpool, United Kingdom, L12 2AP Contact: Rachel Kneen, BMBS    0044 151 2525163    rachel.kneen@liverpool.ac.uk    Principal Investigator: Rachel Kneen, BMBS          Great Ormond Street Hospital Recruiting London, United Kingdom, WC1N 3JH Contact: Christin Eltze, MD Res    0044 207 405 9200 ext 5438    christin.eltze@gosh.nhs.uk    Principal Investigator: Christin Eltze, MD Res          St George's University Hospitals NHS Foundation Trust Recruiting London, United Kingdom Contact: Penny Fallon       Penny.Fallon@stgeorges.nhs.uk    Principal Investigator: Penny Fallon          Royal Manchester Children's Hospital Recruiting Manchester, United Kingdom, M13 0JE Contact: Tim Martland, RCPCH    0044 161 276 1234    timothy.martland@cmft.nhs.uk    Principal Investigator: Tim Martland, RCPCH          The Newcastle Upon Tyne Hospitals NHS Foundation Trust Recruiting Newcastle upon Tyne, United Kingdom Contact: Anita Devlin       Anita.Devlin@nuth.nhs.uk    Principal Investigator: Anita Devlin          Sheffield Children's NHS Foundation Trust Recruiting Sheffield, United Kingdom Contact: Archana Desurkar       Archana.Desurkar@sch.nhs.uk    Principal Investigator: Archana Desurkar 收起 <<
NCT00552526 Epilepsy Ment... 展开 >>al Retardation 收起 << Phase 4 Unknown December 2013 Norway ... 展开 >> SSE, Nevrological dep. , Rikshospitalet University hospital Oslo, Norway 收起 <<
NCT01212458 - Completed - Switzerland ... 展开 >> University Hospital Zurich, Institut of Anaesthesiology Zurich, ZH, Switzerland, 8091 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.20mL

0.84mL

0.42mL

20.99mL

4.20mL

2.10mL

41.98mL

8.40mL

4.20mL
参考文献

[1]Wright HM, Chen AV, et al. Pharmacokinetics of oral rufinamide in dogs. J Vet Pharmacol Ther. 2012 Dec;35(6):529-33.

[2]Williams ET, Carlson JE, et al. Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.